PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerviewpress.com
Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment
Go online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory approval in the adjuvant setting of early-stage disease, and there are many more emerging targets against which novel therapies have shown great promise in clinical trials. Patients with lung cancer who have targetable genomic alterations can derive remarkable benefit from these therapies, and thus, broad biomarker testing is essential to identify these patients, as is making the best rational therapies available to them. Many barriers to biomarker testing and appropriate biomarker-driven treatment exist, and there are also significant disparities in lung cancer clinical care and research, but effective steps can be taken to overcome them. An essential component of modern lung cancer management is patient education, which allows patients to become well-informed participants in their care and participate in shared decision-making with their multidisciplinary clinical teams. This PeerView educational activity, based on a recent web broadcast and developed in collaboration with the LUNGevity Foundation, brings together leading experts in lung cancer, patients, and advocates who engage in candid conversations and clinical consultations focused on how to navigate the increasing complexity of biomarker testing and targeted therapy in lung cancer, and provide the best possible care to all patients. Upon completion of this accredited CE activity, participants should be better able to: Describe established, new, and emerging genomic alterations with potential for therapeutic targeting in NSCLC, Discuss the increasing importance of broad biomarker testing for clinical decision-making and the latest methods for identifying genomic alterations in NSCLC, Compare the mechanisms of action, efficacy, and safety of precision therapies targeting established, new, and emerging molecular alterations in NSCLC, Implement best practices, collaborative strategies, and shared decision-making to ensure widespread biomarker testing, precision treatment, and equitable care of diverse populations of patients with NSCLC in the context of clinical practice or clinical trials.